Results 241 to 250 of about 117,631 (302)

Long‐term efficacy of abrocitinib in patients with moderate‐to‐severe atopic dermatitis to 2 years

Journal of the European Academy of Dermatology and Venereology, EarlyView.
JADE EXTEND is an ongoing phase 3, long‐term extension study of previous abrocitinib trials. Patients were adults and adolescents ≥12 years with moderate‐to‐severe atopic dermatitis. Long‐term abrocitinib treatment resulted in clinically meaningful outcomes and improvements in patient‐reported outcomes up to Week 112 in patients with moderate‐to‐severe
Melinda J. Gooderham, Jonathan I. Silverberg, Marjolein De Bruin‐Weller, Leon Kircik, Diamant Thaçi, Zuotao Zhao, Fernando Valenzuela, Toshifumi Nomura, Andrew Selfridge, Dorothy Fan, Daniela E. Myers, Pinaki Biswas, Saleem A. Farooqui, Melissa Watkins, Herwig Koppensteiner   +14 more
wiley   +1 more source

Janus kinase and calcineurin-inhibitor combination in anti-MDA5 dermatomyositis: No significant survival benefit but reassuring safety profile. [PDF]

J Intern Med
Pagis V, Astouati Q, Pacoureau L, Nguyen Y, Bay P, Roux A, Gallay L, Cottin V, Terrier B, Meyer A, Cerf C, Neuville M, Hervier B, Renaud A, Suzon B, Schleinitz N, Papo T, Priou P, Mekinian A, Ullmer A, Oehler E, Gensous N, Berezne A, Martin LS, Marhadour T, Martin M, Servettaz A, Samson M, Gilardin L, Charles P, Woessner J, Carmoi T, Dilly B, Mauhin W, Baillet N, Humbert S, Thoreau B, Lemaitre M, Pendu CL, Loiseau P, Quemeneur T, Blanchard E, Voermans N, Launay D, Nunes H, Benveniste O, Uzunhan Y, Allenbach Y.   +47 more
europepmc   +1 more source

Dupilumab versus tralokinumab in atopic dermatitis: A propensity score adjusted comparison from BioDay

Journal of the European Academy of Dermatology and Venereology, EarlyView.
This multicentre, observational cohort study in adults and adolescents with atopic dermatitis found that dupilumab treatment provides a higher probability of achieving the treatment targets EASI ≤ 7 and NRS‐pruritus ≤ 4 compared with tralokinumab treatment. Absolute EASI and NRS‐pruritus differences were small among responders.
Lian F. van der Gang, Nicolaas P. A. Zuithoff, Inge M. Haeck, Veroniek E. M. Harbers, Simone Stadhouders‐Keet, Klaziena Politiek, Albert J. Oosting, Anneke M. T. van Lynden‐van Nes, Hoo‐Yin Lam, Anne‐Moon van Tuyll van Serooskerken, Shiarra M. Stewart, Antoni Gostynski, Annebeth Flinterman, Berit Velstra, Wouter R. H. Touwslager, Francine C. van Erp, Marie L. A. Schuttelaar, Marjolein S. de Bruin‐Weller, Marlies de Graaf   +18 more
wiley   +1 more source

Janus Kinase Inhibitors During Pregnancy and Adverse Drug Reactions: A Pharmacovigilance Disproportionality Analysis in VigiBase. [PDF]

Clin Transl Sci
Abolhassani N, Noseda R, Dao K, Girardin FR, Bedussi F, Ceschi A, Panchaud A, Winterfeld U.   +7 more
europepmc   +1 more source

OX40/OX40L modulation: A target for regulating T cells in cutaneous inflammatory disorders

Journal of the European Academy of Dermatology and Venereology, EarlyView.
OX40 and OX40L are a co‐stimulatory immune checkpoint pair. Modulation of this pair impacts multiple immune phenotypes and is an attractive target for immunotherapy in dermatological disorders. Trials are underway with the majority in atopic dermatitis and currently in phase 3 trials.
Aditya K. Gupta, Julia Steriopoulos, Vasiliki Economopoulos, Paradi Mirmirani, Vincent Piguet   +4 more
wiley   +1 more source

Revisiting Janus Kinase Inhibitors in Hospitalized COVID-19: Evidence for Baricitinib's Superiority and the Absence of a Class Effect. [PDF]

J Inflamm Res
Gu L, Lin J, Yue J, Liu Z, Huang JA.
europepmc   +1 more source

Janus kinase inhibitors - a role for the treatment of cutaneous T-cell lymphomas? [PDF]

Oncol Rev
Packer SE, Brunner PM.
europepmc   +1 more source

Rheumatoid Arthritis Preceded by Interstitial Lung Disease Controlled by Long-Term Treatment With the Janus Kinase 1-Selective Inhibitor, Filgotinib: A Case Report. [PDF]

Respirol Case Rep
Sato T, Nakazawa S, Yamamoto S, Nagatani K, Sato K.   +4 more
europepmc   +1 more source

Adverse effects of Janus kinase inhibitors with relevance for daily practice in dermatology. [PDF]

J Dtsch Dermatol Ges
Rajput Khokhar A, Ghoreschi K, Huynh J.
europepmc   +1 more source

Efficacy of abrocitinib and dupilumab in itch‐dominant atopic dermatitis: An analysis of 2 trials

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Jonathan I. Silverberg, Marjolein de Bruin‐Weller, Javier Ortiz de Frutos, Juan Francisco Silvestre, Brian Esparza, Daniela E. Myers, Pinaki Biswas, Irene Hernández‐Martín, Erman Güler, Marina Mikheil, Raj Chovatiya   +10 more
wiley   +1 more source